This is an extended proposal from the 2022 economic development agreement between Brazos County and Fujifilm Biotechnologies.

RNA gene scissors (CRISPR-Cas13) are gaining significant attention as a next-generation gene therapy with fewer side effects.

This is a developing news story. Please check back soon for updates. The FDA granted VG801 rare pediatric disease designation ...

A recent study from the Institute of Biomedicine at the University of Eastern Finland shows that the glucocorticoid receptor ...

The US Food and Drug Administration has granted Nuevocor permission to begin a first-in-human trial of NVC-001, a gene therapy it is developing for LMNA-related dilated cardiomyopathy (LMNA-DCM), the ...

Two Italian women in their twenties on Tuesday received pioneering gene therapy for rare hereditary blood diseases in Pavia ...

Facility expansions and over 5,800 CGT/ATMP batches manufactured underscore Cellex's strength as a trusted full-service CDMO in Europe.

The U.S. Food and Drug Administration (FDA) granted platform technology designation to the viral vector used in SRP-9003, an ...

Facility expansions and over 5,800 CGT/ATMP batches manufactured underscore Cellex's strength as a trusted full-service CDMO in Europe. COLOGNE, Germany, June 10, 2025 /PRNewswire/ -- Cellex ...

An autoantibody associated with systemic lupus erythematosus may help improve the performance of immune checkpoint inhibitor ...

LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United States and Europe, who progress rapidly to ...

TOKYO -- A cluster of genes that could open the way to "tailor-made" prevention methods against Alzheimer's based on a person ...